surmount tirzepatide trials once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial SURMOUNT-5: Tirzepatide shows superior weight

They may be prescribed to patients with CKD and co-morbid heart failure, hyperaldosteronism or resistant hypertension

The maximum dose of Ozempic is 2 mg, administered once weekly on the same day and at the same time

Management Of Side Effects: Most side effects are temporary and generally harmless, which resolve on discontinuing the use of I VIT 12 COMBINATION PACK INJECTION 2.5ML

As this class of medications continues to expand, understanding the GI implications of each receptor target becomes increasingly important

Your healthcare team will schedule periodic reviews that typically include: HbA1c testing every 36 months to assess glycaemic control Weight and BMI measurements at each visit Blood pressure monitoring , as weight loss often improves hypertension Lipid profile assessment annually or as clinically indicated Renal function tests (serum creatinine and eGFR), particularly important if severe gastrointestinal side effects occur that could lead to dehydration Review of side effects and tolerability Assessment of injection technique and adherence Cardiovascular outcome trials for tirzepatide are ongoing, investigating its effects on major adverse cardiovascular events